Medicare GLP-1 coverage 2026 Bridge program

Key Takeaways

• Bridge window: July 1, 2026–December 31, 2027 (extended after BALANCE Part D delay).
• Beneficiary cost: $50 copay; manufacturer net price: $245 per monthly supply.
• Operates outside Part D coverage/payment flow; sponsors need not opt in and do not carry Bridge drug risk.
• Not for patients already Part D–eligible for GLP-1s (for example, type 2 diabetes, OSA, eligible MASH).

What is the Medicare GLP-1 Bridge?

CMS describes the Bridge as a short-term demonstration that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs. It uses Section 402 demonstration authority to test whether new payment methods improve efficiency and economy of Medicare-covered services.

In 2026, CMS will use a single central processor for prior authorization, claims adjudication, and pharmacy payment. Details live on the CMS Medicare GLP-1 Bridge page.

How do pricing and Part D accounting work?

Per CMS’s June 10, 2026 Part D sponsor FAQ memorandum, participating manufacturers supply eligible GLP-1s at a $245 net monthly price. Eligible beneficiaries pay a $50 copay. Because Bridge fills sit outside Part D benefit payment flow:

• The Part D deductible does not apply to Bridge fills.
• No part of the $50 copay counts toward true out-of-pocket costs (TrOOP).
• Low-income subsidy cost-sharing rules do not apply to the Bridge copay structure described by CMS.
• Part D sponsors do not bear financial risk for Bridge-furnished eligible GLP-1s.

Source: Medicare GLP-1 Bridge Expectations and FAQs (PDF).

Who qualifies—and who must stay on Part D?

The Bridge targets weight-management GLP-1 use for Part D enrollees who would not otherwise have access through Part D. CMS is explicit that beneficiaries already eligible for GLP-1 coverage through Part D—regardless of formulary placement—are not Bridge-eligible.

Diagnoses that remain Part D pathways (and therefore Bridge exclusions when coverable) include type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with moderate-to-advanced fibrosis, among other coverable uses CMS cites. Plans must not steer those patients into the Bridge.

Why does BALANCE’s delay matter for BD teams?

CMS extended the Bridge through December 31, 2027 after delaying Part D implementation of the BALANCE Innovation Center model. For manufacturers, PBMs, and investors, that means a longer temporary access channel with fixed $245/$50 economics before any durable Part D obesity coverage design.

Monitoring risk: CMS says it will watch for improper shifting of Part D–eligible members onto the Bridge and can act under 42 CFR 423.752 for noncompliance. Plans must keep covering GLP-1s for indications that remain Part D–coverable under Contract Year 2026 bids and must not tighten exceptions to push members toward the Bridge.

What should commercial and medical teams prepare before July 1?

Prescribers should expect prior authorization through the CMS central processor rather than the patient’s Part D plan for Bridge claims. CMS has said it will not accept Bridge prior-authorization requests before July 1, 2026. Pharmacies need to distinguish Bridge adjudication from standard Part D claims so deductible and TrOOP logic do not incorrectly apply.

Manufacturer account teams should map which products are “eligible GLP-1 drugs” under the Bridge list as CMS posts updates, and align patient-support scripts with the $50 copay / $245 net-price structure. Competitive intelligence should track how many Part D lives sit in plan types CMS lists as Bridge-eligible versus excluded plan designs.

What remains unproven

The demonstration will generate utilization data; it does not yet prove long-term Medicare budget impact, adherence durability, or outcomes parity with commercial obesity coverage. Exact drug lists and operational pharmacy workflows can still update before and after July 1, 2026—teams should track the CMS Bridge pages rather than third-party summaries. Whether Bridge volume later informs a revised BALANCE launch timeline remains a policy unknown, not a settled CMS commitment.

Related NovaPharma coverage

• Weight-loss disease intelligence hub
• Weight-management disease hub
• MariTide Phase 2 obesity data coverage

Frequently Asked Questions

Primary Sources

1. CMS — Medicare GLP-1 Bridge overview
2. CMS — Bridge Expectations and FAQs (June 10, 2026)
3. ClinicalTrials.gov — related GLP-1 study record NCT07638592